Poseida Therapeutics, Inc. (NASDAQ:PSTX – Get Rating)’s stock price reached a new 52-week high during trading on Friday . The company traded as high as $7.44 and last traded at $7.44, with a volume of 9438 shares trading hands. The stock had previously closed at $7.11.
Analyst Upgrades and Downgrades
A number of equities research analysts have commented on PSTX shares. BTIG Research reduced their target price on Poseida Therapeutics from $20.00 to $14.00 in a research report on Friday, November 11th. HC Wainwright assumed coverage on Poseida Therapeutics in a report on Wednesday, January 4th. They issued a “buy” rating and a $15.00 price objective on the stock.
Poseida Therapeutics Price Performance
The stock has a market capitalization of $642.90 million, a price-to-earnings ratio of -11.00 and a beta of 0.12. The company has a debt-to-equity ratio of 0.27, a quick ratio of 6.64 and a current ratio of 6.64. The company has a 50 day moving average of $5.50 and a 200 day moving average of $4.24.
Institutional Trading of Poseida Therapeutics
A number of large investors have recently made changes to their positions in PSTX. EcoR1 Capital LLC purchased a new stake in Poseida Therapeutics during the 3rd quarter valued at approximately $9,355,000. Silverarc Capital Management LLC raised its stake in Poseida Therapeutics by 571.1% during the 3rd quarter. Silverarc Capital Management LLC now owns 2,554,277 shares of the company’s stock valued at $9,017,000 after acquiring an additional 2,173,671 shares during the last quarter. Cormorant Asset Management LP purchased a new stake in Poseida Therapeutics during the 3rd quarter valued at approximately $6,531,000. Vanguard Group Inc. raised its stake in Poseida Therapeutics by 79.9% during the 3rd quarter. Vanguard Group Inc. now owns 2,384,866 shares of the company’s stock valued at $8,419,000 after acquiring an additional 1,059,216 shares during the last quarter. Finally, Pentwater Capital Management LP raised its stake in Poseida Therapeutics by 20.3% during the 3rd quarter. Pentwater Capital Management LP now owns 5,975,000 shares of the company’s stock valued at $21,092,000 after acquiring an additional 1,007,773 shares during the last quarter. 46.67% of the stock is owned by institutional investors and hedge funds.
Poseida Therapeutics Company Profile
Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC).
- Get a free copy of the StockNews.com research report on Poseida Therapeutics (PSTX)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for Poseida Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poseida Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.